Abstract
Diet and lifestyle changes have led to worldwide increases in the prevalences of obesity and metabolic syndrome, resulting in substantially greater incidence of nonalcoholic fatty liver disease (NAFLD). NAFLD is considered a hepatic manifestation of metabolic syndrome and is related to diabetes, insulin resistance, central obesity, hyperlipidemia, and hypertension. Nonalcoholic steatohepatitis (NASH) is an entity that describes liver inflammation due to NAFLD. Growing evidence suggests that NAFLD is a multisystem disease with a clinical burden that is not only confined to liver-related morbidity and mortality, but that also affects several extra-hepatic organs and regulatory pathways. Thus, NAFLD is considered an important public health issue, but there is currently no effective therapy for all NAFLD patients in the general population. Studies seeking optimal therapy for NAFLD and NASH have not yet led to development of a universal protocol for treating this growing problem. Several pharmacological agents have been studied in an effort to improve insulin resistance and the proinflammatory mediators that may be responsible for NASH progression. Cardiovascular risk factors are highly prevalent among NASH patients, and the backbon...Continue Reading
Citations
Apr 14, 2016·BioMed Research International·Sheng-xi MengQin Feng
Mar 15, 2016·Gastroenterology·M Shadab Siddiqui, Michael Charlton
Jul 29, 2016·Scientific Reports·Jihan XiaKui Li
May 2, 2017·Biological & Pharmaceutical Bulletin·Hongshan LiDezhou Li
Jun 1, 2017·The Nurse Practitioner·Jessica Wisocky, Sonali Paul
Nov 26, 2016·Archives of Pharmacal Research·Mi-Kyung KimMoon-Ho Son
Apr 11, 2018·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Luciana M A BorémSergio H S Santos
Dec 6, 2017·Journal of Biological Engineering·Ogechi OgokeNatesh Parashurama
Feb 22, 2018·Canadian Journal of Gastroenterology & Hepatology·Tamara Milovanovic AlempijevicTomica Milosavljevic
Sep 12, 2017·Canadian Journal of Physiology and Pharmacology·Hayam AteyyaNagla A El-Sherbeeny
May 31, 2018·Oncotarget·Yating LiLanjuan Li
Apr 5, 2018·Nutrients·Mahmud MahamidAbdulla Watad
Jan 31, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Tingting ShiJunping Shi
Jul 3, 2020·Diabetes, Obesity & Metabolism·Vesna Lukenda ZankoIvana Mikolasevic
Oct 26, 2016·Alimentary Pharmacology & Therapeutics·Y Ilan
Aug 31, 2019·Medicina·Luka VranićSandra Milić
Jun 22, 2017·Terapevticheskiĭ arkhiv·V A Akhmedov, O V Gaus
Apr 22, 2018·Digestive Diseases and Sciences·Yaron Ilan
Jun 23, 2020·Canadian Journal of Gastroenterology & Hepatology·Blanca Martínez SorianoJosé J García
Oct 14, 2020·Prostaglandins & Other Lipid Mediators·Daniel Silva MoraesSérgio Henrique Sousa Santos
Dec 16, 2018·Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids·Chongye FangJun Sheng
Aug 29, 2017·Journal of Medicinal Chemistry·Jurema SchmidtDaniel Merk
Aug 31, 2017·Journal of Agricultural and Food Chemistry·Long WangFeijun Luo